Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model.

tilavonemab (ABBV-8E12) - AbbVie

semorinemab (RG6100) - Roche

gosuranemab (BIIB092) - Biogen

cinpanemab (BIIB054) - Biogen

http://www.ncbi.nlm.nih.gov/pubmed/37658103

Hugo Geerts; Jean-Philippe Courade; Mike Walker; Piet H van der Graaf; Silke Bergeler

Sep 2, 2023